vasopharm GmbH Announces Post Hoc Analyses of Clinical Trial

- Improved neurologic outcome in young adults (18-39 years) with Ronopterin infused early - Significantly less aggressive critical care with maintained renal function in young adults -

Related Keywords

Germany , Glasgow , Glasgow City , United Kingdom , Nostra , Käten , Austria , Switzerland , France , Spain , Harald Schmidt , Kostenloser Wertpapierhandel , John Stover , Ulrich Walter , Erich Schmutzhard , University Of Innsbruck , Drug Monitoring Committee , Clinical Development Plan For Ronopterin , Clinical Development Plan , Medical University , Chief Investigator , Glasgow Outcome Scale , Unfavorable Outcome , Favorable Outcome , Good Recovery , Intensity Level , Chief Medical Officer , Traumatic Brain Injury , Medical School , Clinical Biochemistry , Nitric Oxide Synthase , Glasgow Outcome Score , Full Analysis Set , Glasgow Outcomes Scale , Vasopharm , Mbh , Nnounces , Most , Analyses , Linical , Trials , Traumatic , Rain , Injury ,